Pacritinib M1 metabolite WS

SL-11194

Pacritinib M1 metabolite WS, >98%

CAS No. : [1312603-77-2]

IUPAC Name : (E)-1-(2-(6,11-Dioxa-3-aza-2(4,2)-pyrimidina-1,4(1,3)-dibenzenacyclododecaphan-8-en-44-yloxy)ethyl)pyrrolidin-2-one

Price And Availability
Pack Size	Price in USD	Add To Shopping Cart	Availability	Shipping Status
5MG	Request A Quote		In Stock	Estimated to ship on 20 September 2026
10MG	Request A Quote		In Stock	Estimated to ship on 20 September 2026
25MG	Request A Quote		In Stock	Estimated to ship on 20 September 2026
50MG	Request A Quote		In Stock	Estimated to ship on 20 September 2026
100MG	Request A Quote		In Stock	Estimated to ship on 20 September 2026

Applications : This is a metabolite of Pacritinib, which is an oral tyrosine kinase inhibitor that selectively targets Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3 (FLT3). It is currently being developed as a treatment option for intermediate and high risk myelofibrosis.

References : Hart S. et al.: Leukemia, 25(11), 1751-9, 2011; Hart S. et al.: Blood Cancer J. 1(11), e44, 2011; Komrokji R. S. et al.: Blood, 125(17), 2649-55, 2015.

Storage : Keep container tightly closed under nitrogen or argon and refrigerate for long-term shelf life.

Caution : In case of contact with skin or eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing and gloves.